Just a little sneak peak of our booth set up at @SABCSSanAntonio. The Epic Sciences Biopharma team looks forward to discussing how our technology can inform your clinical development efforts. Visit us 12/7 to 12/9 from 10-5 at booth #529. We look forward to seeing you there.

Want to learn more about how complementary cell-based phenotypic and genomic analysis can inform your #drugdevelopment programs? We look forward to seeing you at @SABCSSanAntonio 12/6 - 12/10 Learn more by emailing us at BD@epicsciences.com #liquidbiopsy #sabcs2022 #breastcancer

We are excited to announce William J. Kullback as CFO of Epic Sciences. Bill’s experience navigating companies through successful expansion and his background in mergers & acquisitions will be critical as Epic moves into the next phase of company growth. https://t.co/pEu1YsHAyi

Epic Sciences will be participating in #PODC2022 in Chicago on October 19th & 20th. We look forward to meeting with collaborators and new potential partners as we all work together to improve care for patients with #cancer. https://t.co/KvOdhy6vly #oncology #clinicaltrials

Listen to the latest @Breastfriends podcast to learn about the numerous obstacles that still remain for patients and clinicians who are battling metastatic breast cancer.  Tune in to the Breast Friends YouTube Channel here:  https://t.co/w6hcnwAL7z

DefineMBC - a new liquid biopsy test from @EpicSciences for those with #metastaticbreastcancer!! Wed 10/12 on #BreastFriendsCancerSupportNetwork Listen https://t.co/eqPGeR4VZF or watch https://t.co/G91CjrcI6V #MBC #liquidbiopsy @INeverLikedPink

Thank you @EpicSciences for the DefineMBC test! Listen to the #breastfriendscancersupportnetwork podcast 10/12 to learn more about how this liquid biopsy test is helping to care for those with #metastaticbreastcancer @Breastfriends

New liquid biopsy test for those with MBC - 9 am PT on Wed 10/12. Listen https://t.co/BVzkozF3EP or watch: https://t.co/xPdArDE8R5 #breastfriendscancersupportnetwork #cancerpodcast #breastfriendspdx#metastaticbreastcancer #MBC #defineMBC #epicsciences #liquidbiopsy

Hiding in Plain Sight: Early, nano-sized signs of breast cancer detected by liquid biopsy https://t.co/YMOBe21G7u @MichelsonMedRF @uscmichelsoncsi @blood_pac @EpicSciences @NCI_CSSI

Great collaboration at the recent #WorldADC conference in San Diego as antibody-drug conjugates gain momentum! CTC-based #liquidbiopsy HER2, TROP2, PSMA, HER3, & Claudin18.2 protein expression can add insights for #ADC development. To learn more, email us at BD@epicsciences.com

Liquid biopsies offer the opportunity to gather information about each patient’s evolving cancer more frequently. Check out "The Impact of PSMA+ CTCs in Men with mCRPC" presented at #ESMO2022. Visit our website to learn more: https://t.co/VuCuT2ysym #prostatecancer #liquidbiopsy

Pleased to share our latest analysis of PROPHECY showing the independent prognostic importance of PSMA+ CTCs in men with mCRPC treated with Abi/Enza. Sets stage for testing in context of PSMA therapy @DukeGUCancer @EpicSciences @EAntonarakis @ThePCCTC @Daniel_J_George

President & CEO of Epic Sciences supporting our 2022 Komen San Diego More Than Pink Walk by serving on the Susan G. Komen Executive Leadership Committee.

We look forward to connecting with our partners at the @World_ADC Conference in San Diego, September 6-9! These are exciting times to be working with partners developing new ADCs that will benefit patients! #WorldADC #biomarkers #cancer #drugdevelopment

Statistician Glenn Heller @MSKCancerCenter; @RonaldChenMD, @alaccetti, and Gina Mazza @MayoCancerCare for health outcomes; @mishabeltran from the correlatives committee, @Decipher_VCYT and @EpicSciences for supporting correlative studies and everyone else who got this running!

Lots of buzz re: PSMA-PET, LuPSMA and biomarkers at #ASCO22.. Our work of serial CTC profiling of PRINCE trial (LuPSMA+pembro): assoc with PET metrics and early change/clearance of PSMA+ CTCs may forecast outcome on LuPSMA 1/2 @DrMHofman @SandhuShahneen @PeterMacRes @EpicSciences

Congratulations, @EpicSciences! The biotech company has raised $43M to advance its liquid biopsy offerings 🥳 Its #SDlifechanging tests are intended to be used when tissue biopsy is inaccessible or infeasible. P.S. They're hiring 👀 https://t.co/zkHQoZ3eqe

“We are continuing to innovate testing for both the research and clinical markets”- Lloyd Sanders, president and CEO of @EpicSciences – as quoted in last week’s @SDBusiness article covering Epic’s recent #funding announcement. https://t.co/SLvBychDzu #liquidbiopsy #diagnostics

Did you happen to see @EpicSciences featured on the @Nasdaq MarketSite in NY Time Square last week? It’s exciting to have world-class investors that are committed to truly partnering with Epic and is a privilege to work with them to invest in improving care for cancer patients.